About Us Services Careers FAQ Contact Us 0
Home Biotechnology Red Biotechnology Market Size to Expect a Growth of USD 1,360 billion by 2032
Red Biotechnology Market

Red Biotechnology Market Size, Share & Trends Analysis Report By Product Type (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Proteins, Vaccines, Cell-Based Immunotherapy Products, Gene Therapy Products, Cell Therapy Products, Tissue-Engineered Products, Stem Cells, Cell Culture, Viral Vector, Enzymes, Kits and Reagents, Animal models, Molecular diagnostics, Others), By Application (Pharmacogenomics, Gene Therapy, Genetic Testing , Biopharmaceutical Production), By End-User (Research Institutes, CMOs and CROs, Pharmaceutical and biotechnology companies, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRBI56066DR
Author : Debashree Bora
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Red Biotechnology Market Introduction
    2. By Application
      1. Introduction
        1. Application By Value
      2. Pharmacogenomics
        1. By Value
      3. Gene Therapy
        1. By Value
      4. Genetic Testing
        1. By Value
      5. Biopharmaceutical Production
        1. By Value
    3. By End-User
      1. Introduction
        1. End-User By Value
      2. Research Institutes
        1. By Value
      3. CMOs and CROs
        1. By Value
      4. Pharmaceutical and biotechnology companies
        1. By Value
      5. Others
        1. By Value
    4. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Monoclonal Antibodies
        1. By Value
      3. Polyclonal Antibodies
        1. By Value
      4. Recombinant Proteins
        1. By Value
      5. Vaccines
        1. By Value
      6. Cell-Based Immunotherapy Products
        1. By Value
      7. Gene Therapy Products
        1. By Value
      8. Cell Therapy Products
        1. By Value
      9. Tissue-Engineered Products
        1. By Value
      10. Stem Cells
        1. By Value
      11. Cell Culture
        1. By Value
      12. Viral Vector
        1. By Value
      13. Enzymes
        1. By Value
      14. Kits and Reagents
        1. By Value
      15. Animal models
        1. By Value
      16. Molecular diagnostics
        1. By Value
      17. Others
        1. By Value
    1. Introduction
    2. By Application
      1. Introduction
        1. Application By Value
      2. Pharmacogenomics
        1. By Value
      3. Gene Therapy
        1. By Value
      4. Genetic Testing
        1. By Value
      5. Biopharmaceutical Production
        1. By Value
    3. By End-User
      1. Introduction
        1. End-User By Value
      2. Research Institutes
        1. By Value
      3. CMOs and CROs
        1. By Value
      4. Pharmaceutical and biotechnology companies
        1. By Value
      5. Others
        1. By Value
    4. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Monoclonal Antibodies
        1. By Value
      3. Polyclonal Antibodies
        1. By Value
      4. Recombinant Proteins
        1. By Value
      5. Vaccines
        1. By Value
      6. Cell-Based Immunotherapy Products
        1. By Value
      7. Gene Therapy Products
        1. By Value
      8. Cell Therapy Products
        1. By Value
      9. Tissue-Engineered Products
        1. By Value
      10. Stem Cells
        1. By Value
      11. Cell Culture
        1. By Value
      12. Viral Vector
        1. By Value
      13. Enzymes
        1. By Value
      14. Kits and Reagents
        1. By Value
      15. Animal models
        1. By Value
      16. Molecular diagnostics
        1. By Value
      17. Others
        1. By Value
    5. U.S.
      1. By Application
        1. Introduction
          1. Application By Value
        2. Pharmacogenomics
          1. By Value
        3. Gene Therapy
          1. By Value
        4. Genetic Testing
          1. By Value
        5. Biopharmaceutical Production
          1. By Value
      2. By End-User
        1. Introduction
          1. End-User By Value
        2. Research Institutes
          1. By Value
        3. CMOs and CROs
          1. By Value
        4. Pharmaceutical and biotechnology companies
          1. By Value
        5. Others
          1. By Value
      3. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Monoclonal Antibodies
          1. By Value
        3. Polyclonal Antibodies
          1. By Value
        4. Recombinant Proteins
          1. By Value
        5. Vaccines
          1. By Value
        6. Cell-Based Immunotherapy Products
          1. By Value
        7. Gene Therapy Products
          1. By Value
        8. Cell Therapy Products
          1. By Value
        9. Tissue-Engineered Products
          1. By Value
        10. Stem Cells
          1. By Value
        11. Cell Culture
          1. By Value
        12. Viral Vector
          1. By Value
        13. Enzymes
          1. By Value
        14. Kits and Reagents
          1. By Value
        15. Animal models
          1. By Value
        16. Molecular diagnostics
          1. By Value
        17. Others
          1. By Value
    6. Canada
    1. Introduction
    2. By Application
      1. Introduction
        1. Application By Value
      2. Pharmacogenomics
        1. By Value
      3. Gene Therapy
        1. By Value
      4. Genetic Testing
        1. By Value
      5. Biopharmaceutical Production
        1. By Value
    3. By End-User
      1. Introduction
        1. End-User By Value
      2. Research Institutes
        1. By Value
      3. CMOs and CROs
        1. By Value
      4. Pharmaceutical and biotechnology companies
        1. By Value
      5. Others
        1. By Value
    4. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Monoclonal Antibodies
        1. By Value
      3. Polyclonal Antibodies
        1. By Value
      4. Recombinant Proteins
        1. By Value
      5. Vaccines
        1. By Value
      6. Cell-Based Immunotherapy Products
        1. By Value
      7. Gene Therapy Products
        1. By Value
      8. Cell Therapy Products
        1. By Value
      9. Tissue-Engineered Products
        1. By Value
      10. Stem Cells
        1. By Value
      11. Cell Culture
        1. By Value
      12. Viral Vector
        1. By Value
      13. Enzymes
        1. By Value
      14. Kits and Reagents
        1. By Value
      15. Animal models
        1. By Value
      16. Molecular diagnostics
        1. By Value
      17. Others
        1. By Value
    5. U.K.
      1. By Application
        1. Introduction
          1. Application By Value
        2. Pharmacogenomics
          1. By Value
        3. Gene Therapy
          1. By Value
        4. Genetic Testing
          1. By Value
        5. Biopharmaceutical Production
          1. By Value
      2. By End-User
        1. Introduction
          1. End-User By Value
        2. Research Institutes
          1. By Value
        3. CMOs and CROs
          1. By Value
        4. Pharmaceutical and biotechnology companies
          1. By Value
        5. Others
          1. By Value
      3. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Monoclonal Antibodies
          1. By Value
        3. Polyclonal Antibodies
          1. By Value
        4. Recombinant Proteins
          1. By Value
        5. Vaccines
          1. By Value
        6. Cell-Based Immunotherapy Products
          1. By Value
        7. Gene Therapy Products
          1. By Value
        8. Cell Therapy Products
          1. By Value
        9. Tissue-Engineered Products
          1. By Value
        10. Stem Cells
          1. By Value
        11. Cell Culture
          1. By Value
        12. Viral Vector
          1. By Value
        13. Enzymes
          1. By Value
        14. Kits and Reagents
          1. By Value
        15. Animal models
          1. By Value
        16. Molecular diagnostics
          1. By Value
        17. Others
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Application
      1. Introduction
        1. Application By Value
      2. Pharmacogenomics
        1. By Value
      3. Gene Therapy
        1. By Value
      4. Genetic Testing
        1. By Value
      5. Biopharmaceutical Production
        1. By Value
    3. By End-User
      1. Introduction
        1. End-User By Value
      2. Research Institutes
        1. By Value
      3. CMOs and CROs
        1. By Value
      4. Pharmaceutical and biotechnology companies
        1. By Value
      5. Others
        1. By Value
    4. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Monoclonal Antibodies
        1. By Value
      3. Polyclonal Antibodies
        1. By Value
      4. Recombinant Proteins
        1. By Value
      5. Vaccines
        1. By Value
      6. Cell-Based Immunotherapy Products
        1. By Value
      7. Gene Therapy Products
        1. By Value
      8. Cell Therapy Products
        1. By Value
      9. Tissue-Engineered Products
        1. By Value
      10. Stem Cells
        1. By Value
      11. Cell Culture
        1. By Value
      12. Viral Vector
        1. By Value
      13. Enzymes
        1. By Value
      14. Kits and Reagents
        1. By Value
      15. Animal models
        1. By Value
      16. Molecular diagnostics
        1. By Value
      17. Others
        1. By Value
    5. China
      1. By Application
        1. Introduction
          1. Application By Value
        2. Pharmacogenomics
          1. By Value
        3. Gene Therapy
          1. By Value
        4. Genetic Testing
          1. By Value
        5. Biopharmaceutical Production
          1. By Value
      2. By End-User
        1. Introduction
          1. End-User By Value
        2. Research Institutes
          1. By Value
        3. CMOs and CROs
          1. By Value
        4. Pharmaceutical and biotechnology companies
          1. By Value
        5. Others
          1. By Value
      3. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Monoclonal Antibodies
          1. By Value
        3. Polyclonal Antibodies
          1. By Value
        4. Recombinant Proteins
          1. By Value
        5. Vaccines
          1. By Value
        6. Cell-Based Immunotherapy Products
          1. By Value
        7. Gene Therapy Products
          1. By Value
        8. Cell Therapy Products
          1. By Value
        9. Tissue-Engineered Products
          1. By Value
        10. Stem Cells
          1. By Value
        11. Cell Culture
          1. By Value
        12. Viral Vector
          1. By Value
        13. Enzymes
          1. By Value
        14. Kits and Reagents
          1. By Value
        15. Animal models
          1. By Value
        16. Molecular diagnostics
          1. By Value
        17. Others
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Singapore
    11. Taiwan
    12. South East Asia
    13. Rest of Asia-Pacific
    1. Introduction
    2. By Application
      1. Introduction
        1. Application By Value
      2. Pharmacogenomics
        1. By Value
      3. Gene Therapy
        1. By Value
      4. Genetic Testing
        1. By Value
      5. Biopharmaceutical Production
        1. By Value
    3. By End-User
      1. Introduction
        1. End-User By Value
      2. Research Institutes
        1. By Value
      3. CMOs and CROs
        1. By Value
      4. Pharmaceutical and biotechnology companies
        1. By Value
      5. Others
        1. By Value
    4. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Monoclonal Antibodies
        1. By Value
      3. Polyclonal Antibodies
        1. By Value
      4. Recombinant Proteins
        1. By Value
      5. Vaccines
        1. By Value
      6. Cell-Based Immunotherapy Products
        1. By Value
      7. Gene Therapy Products
        1. By Value
      8. Cell Therapy Products
        1. By Value
      9. Tissue-Engineered Products
        1. By Value
      10. Stem Cells
        1. By Value
      11. Cell Culture
        1. By Value
      12. Viral Vector
        1. By Value
      13. Enzymes
        1. By Value
      14. Kits and Reagents
        1. By Value
      15. Animal models
        1. By Value
      16. Molecular diagnostics
        1. By Value
      17. Others
        1. By Value
    5. UAE
      1. By Application
        1. Introduction
          1. Application By Value
        2. Pharmacogenomics
          1. By Value
        3. Gene Therapy
          1. By Value
        4. Genetic Testing
          1. By Value
        5. Biopharmaceutical Production
          1. By Value
      2. By End-User
        1. Introduction
          1. End-User By Value
        2. Research Institutes
          1. By Value
        3. CMOs and CROs
          1. By Value
        4. Pharmaceutical and biotechnology companies
          1. By Value
        5. Others
          1. By Value
      3. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Monoclonal Antibodies
          1. By Value
        3. Polyclonal Antibodies
          1. By Value
        4. Recombinant Proteins
          1. By Value
        5. Vaccines
          1. By Value
        6. Cell-Based Immunotherapy Products
          1. By Value
        7. Gene Therapy Products
          1. By Value
        8. Cell Therapy Products
          1. By Value
        9. Tissue-Engineered Products
          1. By Value
        10. Stem Cells
          1. By Value
        11. Cell Culture
          1. By Value
        12. Viral Vector
          1. By Value
        13. Enzymes
          1. By Value
        14. Kits and Reagents
          1. By Value
        15. Animal models
          1. By Value
        16. Molecular diagnostics
          1. By Value
        17. Others
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Application
      1. Introduction
        1. Application By Value
      2. Pharmacogenomics
        1. By Value
      3. Gene Therapy
        1. By Value
      4. Genetic Testing
        1. By Value
      5. Biopharmaceutical Production
        1. By Value
    3. By End-User
      1. Introduction
        1. End-User By Value
      2. Research Institutes
        1. By Value
      3. CMOs and CROs
        1. By Value
      4. Pharmaceutical and biotechnology companies
        1. By Value
      5. Others
        1. By Value
    4. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Monoclonal Antibodies
        1. By Value
      3. Polyclonal Antibodies
        1. By Value
      4. Recombinant Proteins
        1. By Value
      5. Vaccines
        1. By Value
      6. Cell-Based Immunotherapy Products
        1. By Value
      7. Gene Therapy Products
        1. By Value
      8. Cell Therapy Products
        1. By Value
      9. Tissue-Engineered Products
        1. By Value
      10. Stem Cells
        1. By Value
      11. Cell Culture
        1. By Value
      12. Viral Vector
        1. By Value
      13. Enzymes
        1. By Value
      14. Kits and Reagents
        1. By Value
      15. Animal models
        1. By Value
      16. Molecular diagnostics
        1. By Value
      17. Others
        1. By Value
    5. Brazil
      1. By Application
        1. Introduction
          1. Application By Value
        2. Pharmacogenomics
          1. By Value
        3. Gene Therapy
          1. By Value
        4. Genetic Testing
          1. By Value
        5. Biopharmaceutical Production
          1. By Value
      2. By End-User
        1. Introduction
          1. End-User By Value
        2. Research Institutes
          1. By Value
        3. CMOs and CROs
          1. By Value
        4. Pharmaceutical and biotechnology companies
          1. By Value
        5. Others
          1. By Value
      3. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Monoclonal Antibodies
          1. By Value
        3. Polyclonal Antibodies
          1. By Value
        4. Recombinant Proteins
          1. By Value
        5. Vaccines
          1. By Value
        6. Cell-Based Immunotherapy Products
          1. By Value
        7. Gene Therapy Products
          1. By Value
        8. Cell Therapy Products
          1. By Value
        9. Tissue-Engineered Products
          1. By Value
        10. Stem Cells
          1. By Value
        11. Cell Culture
          1. By Value
        12. Viral Vector
          1. By Value
        13. Enzymes
          1. By Value
        14. Kits and Reagents
          1. By Value
        15. Animal models
          1. By Value
        16. Molecular diagnostics
          1. By Value
        17. Others
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Red Biotechnology Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Amgen Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Gilead Sciences, Inc.
    3. Biogen
    4. Pfizer Inc.
    5. Novartis AG
    6. Hoffmann-La Roche
    7. Johnson and Johnson Services, Inc.
    8. Sanofi
    9. Merck & Co. Inc.
    10. AbbVie Inc.
    11. GSK plc.
    12. AstraZeneca
    13. Eli Lilly and Company
    14. Novo Nordisk A/S
    15. Bayer AG
    16. Bristol-Myers Squibb Company
    17. Teva Pharmaceutical Industries Ltd.
    18. Takeda Pharmaceutical Company Limited
    19. Boehringer Ingelheim International GmbH
    20. Astellas Pharma Inc. 
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Market Overview The global Ablation Technology market size is registering a CAGR of 9.54% during the forecast period 2023-2031. Ablation technology is the process of removing part of biological tissue by surgery. Ablation devices offer a minim
Buy Now
Global Report
Biotechnology Market Size The global biotechnology market size was valued at USD 1.75 trillion in 2024 and is estimated to grow from USD 1.96 trillion in 2025 to reach USD 5.04 trillion by 2033, growing at a CAGR of 12.48% during the forecast p
Buy Now
Global Report
Market OverviewThe global food biotechnology market size was valued at USD 21.43 billion in 2023 and is projected to reach a value of USD 51.79 billion by 2032, registering a CAGR of 10.30% during the forecast period (2024-2032). The increase in food
Buy Now
Global Report
The global forensic technology market size was valued at USD 14.78 billion in 2021 and is projected to reach USD 41.92 billion by 2030, registering a CAGR of 12.28% from 2022 to 2030. The processing of forensic samples and evidence is essential
Buy Now
Global Report
The global simultaneous localization and mapping (SLAM) technology market size was valued at USD 226.7 million in 2021. It is expected to reach USD 9,425.7 million by 2030, growing at a CAGR of 49.41% during the forecast period (2
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright . All rights Reserved.